Taysha Gene Therapies, Inc. Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc.

TSHA

Rank in Stocks #6466
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and... Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Share Price
$4.10
Last synced: 2026-11-13
Market Cap
$1.67B
Change (1 day)
-2.61%
Change (1 year)
2.76%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Trade Taysha Gene Therapies, Inc. (TSHA)

Category

Healthcare
EPS for Taysha Gene Therapies, Inc. (TSHA)
EPS as of September 2026 TTM: $-0.43
According to Taysha Gene Therapies, Inc.'s latest financial reports, its current EPS (TTM) is $-0.43. At the end of 2025 the company had an EPS of $-0.34, an increase over its 2024 EPS of $-0.36.
EPS history for Taysha Gene Therapies, Inc. from 2019 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-0.43 26.47%
2025 $-0.34 -5.56%
2024 $-0.36 -62.50%
2023 $-0.96 -74.60%
2022 $-3.78 -18.53%
2021 $-4.64 36.47%
2020 $-3.40 11,195.68%
2019 $-0.03 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$-0.89 106.98%
US
$15.66 -3,741.86%
US
$-7.07 1,544.19%
US
$-5.29 1,130.23%
AU
$12.73 -3,060.98%
BE

Questions about Taysha Gene Therapies, Inc.'s earnings per share (EPS)

What is Taysha Gene Therapies, Inc.'s earnings per share (EPS)?

Taysha Gene Therapies, Inc.'s earnings per share (EPS) over the last twelve months is $-0.43, as of Sep 2026.

What was Taysha Gene Therapies, Inc.'s earnings per share (EPS) in 2025?

In 2025, Taysha Gene Therapies, Inc.'s earnings per share (EPS) was $-0.34, compared with $-0.36 in 2024.

How has Taysha Gene Therapies, Inc.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, Taysha Gene Therapies, Inc.'s earnings per share (EPS) was highest in 2025 ($-0.34) and lowest in 2021 ($-4.64).

How does Taysha Gene Therapies, Inc.'s earnings per share (EPS) compare with similar companies?

Taysha Gene Therapies, Inc.'s earnings per share (EPS) ($-0.43) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.